MRI-derived radiogenomic surrogate of a hypoxia–angiogenesis–EMT transcriptional state in nasopharyngeal carcinoma: multicenter external validation
Frontiers in Molecular Biosciences · 05.11.2026 · 13
DOI: 10.3389/fmolb.2026.1968989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Molecular Biosciences, online erschienen am 05.11.2026. Verfasst von Zhichao Zuo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Central Hospital of Xiangtan (The Affiliated Hospital of Hunan University), Xiangtan, China. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study aimed to develop a pretreatment MRI-derived radiogenomic surrogate of a prespecified hypoxia–angiogenesis–epithelial–mesenchymal transition transcriptional state and to evaluate its associations with treatment response and survival in nasopharyngeal carcinoma.
Methods
This multicenter observational study integrated patient-derived public transcriptomic datasets, experimental CNE2/CNE2-IR radioresistance models, a prospective RNA-sequencing cohort of 49 patients with paired contrast-enhanced T1-weighted MRI and RNA data, and two independent clinical cohorts (n = 532 and n = 118). HAE-CAS was the equal-weight mean of three within-cohort standardized module scores. Treatment response was assessed approximately 3 months after chemoradiotherapy according to RECIST version 1.1 using nasopharyngeal MRI, nasopharyngoscopy, and clinical evaluation. Rad-HAE used a five-feature Gaussian ridge model and was evaluated with 20 repetitions of five-fold nested cross-validation; response and survival outcomes were excluded from model development.
Results
Among 49 response-evaluable RNA-sequenced patients, 17 had complete response (CR) and 32 had partial response (PR); no stable or progressive disease occurred. HAE-CAS was higher in PR than CR (rank-biserial correlation = 0.365, P = 0.035). In GSE102349, continuous HAE-CAS was not significantly associated with progression-free survival (HR per 1-SD increase = 1.20, 95% CI 0.74–1.95; P = 0.465), whereas the median-dichotomized comparison was exploratory (log-rank P = 0.024). Aggregated out-of-fold Rad-HAE correlated with HAE-CAS (Spearman rho = 0.637, P < 0.001) and discriminated PR from CR among 49 paired response-evaluable patients (AUC = 0.846, 95% CI 0.732–0.943). In two independent clinical cohorts, higher Rad-HAE was associated with shorter progression-free and overall survival.
Conclusion
Pretreatment CE-T1WI radiomics was associated with interpatient variation in a prespecified composite HAE transcriptional state. Rad-HAE represents an imaging-based surrogate associated with the composite HAE transcriptional state and does not directly quantify individual biological processes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, The Central Hospital of Xiangtan (The Affiliated Hospital of Hunan University), Xiangtan, China.
- Medical Imaging Department, Guangxi Medical University Cancer Hospital, Nanning, China.
- Department of Radiation Oncology, Wuzhou Red Cross Hospital, Wuzhou, China.
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Zitieren
APA
Zuo, Z., Zhu, T., Lu, Y., Zeng, X., & Liu, Y. (2026). MRI-derived radiogenomic surrogate of a hypoxia–angiogenesis–EMT transcriptional state in nasopharyngeal carcinoma: multicenter external validation. Frontiers in Molecular Biosciences, 13. https://doi.org/10.3389/fmolb.2026.1968989
Vancouver
Zuo Z, Zhu T, Lu Y, Zeng X, Liu Y. MRI-derived radiogenomic surrogate of a hypoxia–angiogenesis–EMT transcriptional state in nasopharyngeal carcinoma: multicenter external validation. Frontiers in Molecular Biosciences. 2026;13. doi:10.3389/fmolb.2026.1968989
BibTeX
@article{Zuo2026,
author = {Zuo, Zhichao and Zhu, Ting and Lu, Yixin and Zeng, Xiaoyi and Liu, Yang},
title = {MRI-derived radiogenomic surrogate of a hypoxia–angiogenesis–EMT transcriptional state in nasopharyngeal carcinoma: multicenter external validation},
journal = {Frontiers in Molecular Biosciences},
year = {2026},
volume = {13},
doi = {10.3389/fmolb.2026.1968989}
}
EUVIMED